{"id":49352,"date":"2024-07-24T13:54:58","date_gmt":"2024-07-24T13:54:58","guid":{"rendered":"https:\/\/newonclusivstg.wpengine.com\/?p=49352"},"modified":"2026-05-21T13:18:18","modified_gmt":"2026-05-21T13:18:18","slug":"the-impact-of-glp-1-weight-loss-drugs-on-the-food-beverage-industry-a-media-monitoring-analysis","status":"publish","type":"post","link":"https:\/\/onclusive.com\/en-gb\/resources\/blog\/the-impact-of-glp-1-weight-loss-drugs-on-the-food-beverage-industry-a-media-monitoring-analysis\/","title":{"rendered":"The Impact of GLP-1 Weight Loss Drugs on the Food &amp; Beverage Industry: A Media Monitoring Analysis"},"content":{"rendered":"\n<section\n    class=\"block-pcon\">\n\n      \n\t\t\t<div class=\"post_content--wrapper\">\n\t\t\t\t<div class=\"post_content--copy  \">\n\t\t\t\t\t<div class=\"post_content--copy-inner-wrapper\">\n\n\n\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"post_content-copy-wrapper\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t  \t\t<p><strong>The rise of GLP-1 weight loss medications, such as Wegovy and Ozempic are revolutionizing weight management. This development brings both opportunities and threats for many industries, with the Food &amp; Beverage sector being particularly affected. Media coverage provides crucial insights into how companies are responding to the rise of GLP-1 weight loss medications and how their strategies are being perceived by the public and industry experts.\u00a0<\/strong><\/p>\n<p>In our recent report, <span style=\"font-weight: 400;\">&#8220;<a href=\"https:\/\/onclusive.com\/en-gb\/resources\/whitepaper\/ceo-index-food-and-beverages\/\">Food &amp; Beverage CEOs and Their Brands in the Media<\/a>,&#8221;<\/span><span style=\"font-weight: 400;\"> we analyzed media coverage of leading global Food &amp; Beverage industry CEOs and their companies to understand the key issues shaping the industry. A significant theme that emerged was the impact of GLP-1 weight loss drugs. This blog post explores this topic in more detail<br \/>\nFor our mainstream media analysis, we used Onclusive\u2019s media monitoring tool to focus on seven major brands and their CEOs from our report:<\/span><\/p>\n<ul>\n<li><strong>Danone<\/strong><\/li>\n<li><strong>Diageo<\/strong><\/li>\n<li><strong>Glanbia<\/strong><\/li>\n<li><strong>Mondelez International<\/strong><\/li>\n<li><strong>Nestl\u00e9<\/strong><\/li>\n<li><strong>PepsiCo<\/strong><\/li>\n<\/ul>\n<h2><\/h2>\n<h3><span style=\"font-weight: 400;\">GLP-1 &amp; Food &amp; Beverage Brands Media Mentions Over Time<\/span><\/h3>\n<h4><span style=\"font-weight: 400;\">Onclusive\u2019s media monitoring tool revealed that between April 1 and July 11, 2024, there were 3,610 mainstream media mentions of GLP-1 in connection with the seven brands analyzed. Nestl\u00e9 emerged as the clear leader, accounting for 58% of the total Share of Voice (SoV) with 1,954 mentions. Danone followed with 14% SoV, and Glanbia came in third with 11%.<\/span><\/h4>\n<figure id=\"attachment_49354\" aria-describedby=\"caption-attachment-49354\" style=\"width: 512px\" class=\"wp-caption aligncenter\"><img fetchpriority=\"high\" decoding=\"async\" fetchpriority=\"high\" class=\"wp-image-49354 size-full\" src=\"https:\/\/onclusive.com\/wp-content\/uploads\/2024\/07\/Brand-mentions-FB.png\" alt=\"Brand Mentions in Relation to GLP-1 Drugs (April 1 - July 11, 2024) -The Impact of GLP-1 Weight Loss Drugs on the Food &amp; Beverage Industry: A Media Monitoring Analysis\" width=\"512\" height=\"341\" srcset=\"https:\/\/onclusive.com\/wp-content\/uploads\/2024\/07\/Brand-mentions-FB.png 512w, https:\/\/onclusive.com\/wp-content\/uploads\/2024\/07\/Brand-mentions-FB-300x200.png 300w\" sizes=\"(max-width: 639px) 98vw, (max-width: 1199px) 64vw, 512px\" \/><figcaption id=\"caption-attachment-49354\" class=\"wp-caption-text\">Brand Mentions in Relation to GLP-1 Drugs (April 1 &#8211; July 11, 2024)<\/figcaption><\/figure>\n<p>&nbsp;<\/p>\n<figure id=\"attachment_49361\" aria-describedby=\"caption-attachment-49361\" style=\"width: 512px\" class=\"wp-caption aligncenter\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-49361\" src=\"https:\/\/onclusive.com\/wp-content\/uploads\/2024\/07\/unnamed-300x200.png\" alt=\"Brand Share of Voice in Relation to GLP-1 Drugs (April 1 - July 11, 2024)-The Impact of GLP-1 Weight Loss Drugs on the Food &amp; Beverage Industry: A Media Monitoring Analysis\" width=\"512\" height=\"341\" srcset=\"https:\/\/onclusive.com\/wp-content\/uploads\/2024\/07\/unnamed-300x200.png 300w, https:\/\/onclusive.com\/wp-content\/uploads\/2024\/07\/unnamed-1024x683.png 1024w, https:\/\/onclusive.com\/wp-content\/uploads\/2024\/07\/unnamed-768x512.png 768w, https:\/\/onclusive.com\/wp-content\/uploads\/2024\/07\/unnamed-640x427.png 640w, https:\/\/onclusive.com\/wp-content\/uploads\/2024\/07\/unnamed.png 1200w\" sizes=\"(max-width: 639px) 98vw, (max-width: 1199px) 64vw, 512px\" \/><figcaption id=\"caption-attachment-49361\" class=\"wp-caption-text\">Brand Share of Voice in Relation to GLP-1 Drugs (April 1 &#8211; July 11, 2024)<\/figcaption><\/figure>\n<p>&nbsp;<\/p>\n<h3><span style=\"font-weight: 400;\">Key Insights from our Media Monitoring Analysis\u00a0<\/span><\/h3>\n<h4><b>Nestl\u00e9<\/b><b>:<\/b><\/h4>\n<p><span style=\"font-weight: 400;\">On May 21, N<\/span><span style=\"font-weight: 400;\">estl\u00e9&#8217;s media coverage peaked following the announcement of its new &#8220;Vital Pursuit&#8221; product line aimed at GLP-1 drug users. This line includes whole grain bowls, protein pasta, sandwich melts, and pizza designed to support weight management efforts. This follows suit with health companies that plan to launch similar products this year.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">On June 25, the brand had a significant surge in media coverage when Nestl\u00e9 Health Science launched its GLP-1 nutrition platform &#8211; a new web platform that provides comprehensive support for people on GLP-1 medications.<\/span><b><\/b><\/p>\n<h4><b>Danone:<\/b><\/h4>\n<p><span style=\"font-weight: 400;\">Danone gained 453 mainstream media mentions. On May 28, Danone featured in headlines including \u201cWellness Supplements Market Size to Worth USD 454.86 Bn By 2031\u201d, though these mentions were not highly significant. However, on June 20, Danone was frequently cited in headlines alongside other brands in our analysis: \u201cNestle, Coke, Danone take cautious approach to catering to Ozempic users\u201d<\/span><b><\/b><\/p>\n<h4><b>Glanbia:<\/b><\/h4>\n<p><span style=\"font-weight: 400;\">Glanbia achieved 369 article mentions overall. On April 25, the brand saw a peak in coverage (340 mentions) when it was discussed alongside Nestl\u00e9 in articles about the potential threat of weight loss drugs like Ozempic and Wegovy to the diet industry.<\/span><b><\/b><\/p>\n<p><span style=\"font-weight: 400;\">Food &amp; Beverage industry leaders are beginning to acknowledge the potential impact of GLP-1 medications. However, only a few are actively contributing to and shaping their brand\u2019s narrative on this topic.<\/span><\/p>\n<figure id=\"attachment_49368\" aria-describedby=\"caption-attachment-49368\" style=\"width: 512px\" class=\"wp-caption aligncenter\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-49368 size-full\" src=\"https:\/\/onclusive.com\/wp-content\/uploads\/2024\/07\/unnamed-1.png\" alt=\"CEO Share of Voice on GLP-1 drugs (April 1 - July 11 2024) -The Impact of GLP-1 Weight Loss Drugs on the Food &amp; Beverage Industry: A Media Monitoring Analysis\" width=\"512\" height=\"341\" srcset=\"https:\/\/onclusive.com\/wp-content\/uploads\/2024\/07\/unnamed-1.png 512w, https:\/\/onclusive.com\/wp-content\/uploads\/2024\/07\/unnamed-1-300x200.png 300w\" sizes=\"(max-width: 639px) 98vw, (max-width: 1199px) 64vw, 512px\" \/><figcaption id=\"caption-attachment-49368\" class=\"wp-caption-text\">CEO Share of Voice on GLP-1 drugs (April 1 &#8211; July 11 2024)<\/figcaption><\/figure>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<h4><b>Nestl\u00e9 CEO Ulf Mark Schneider<\/b><\/h4>\n<p><span style=\"font-weight: 400;\">Most CEOs in our list were not heavily featured in mainstream news coverage on this topic during the analyzed time frame. However, Nestl\u00e9 CEO Ulf Mark Schneider was an exception, accounting for 80% SoV with 454 mentions. He was quoted in articles with headlines such as \u201cWhat do weight-loss drugs mean for a diet industry built on eating less and exercising more?\u201d Schneider remarked, \u201cDiets are cool again. It\u2019s something that people used to do quietly on the side, uncertain about their outcomes.\u201d<\/span><\/p>\n<h4><b>Danone CEO Antoine de Saint-Affrique<\/b><\/h4>\n<p><span style=\"font-weight: 400;\">Antoine de Saint-Affrique received 79 mentions. In April, he was quoted in headlines downplaying the threat of weight loss drugs to food producers: \u201cWe see ourselves as extremely complementary,\u201d he said, emphasizing Danone\u2019s role in providing essential proteins.<\/span><\/p>\n<h2><b>\u00a0<\/b><\/h2>\n<h4><b>Mondelez CEO, Dirk Van de Put<\/b><\/h4>\n<p><span style=\"font-weight: 400;\">Despite Mondelez International sitting in third place with 5% of the global SoV regarding GLP-1 drugs, it\u2019s CEO, Dirk Van de Put, continues to shrug off worries that weight loss drugs will impact the food industry saying that he expects that in 10 years, the drug\u2019s effect on sales volumes will equate to a \u201cmargin of error\u201d\u2014between 0.5% and 1%<\/span> <span style=\"font-weight: 400;\">&#8211; echoing the comments that other major brands made at the end of 2023. However, Mondelez has been quoted as saying that its snack bars fit perfectly into the diet of a GLP-1 patient in articles that discuss the launch of <\/span><span style=\"font-weight: 400;\">Nestl\u00e9<\/span><span style=\"font-weight: 400;\">\u2019s pizza range for Ozempic users.<\/span><\/p>\n<h2><b>\u00a0<\/b><\/h2>\n<h4><b>Coca-Cola CEO James Quincey<\/b><span style=\"font-weight: 400;\">\u00a0<\/span><\/h4>\n<p><span style=\"font-weight: 400;\">James Quincey was featured in a few articles, noting the industry&#8217;s shift towards health and wellness and the opportunity to innovate and offer more health-conscious products. Similarly, PepsiCo CEO Ramon Laguarta received little coverage in the analyzed period but had previously downplayed the threat of GLP-1 drugs to PepsiCo\u2019s business.<\/span><\/p>\n<h2><b>\u00a0<\/b><\/h2>\n<p><b>What\u2019s Next for the Food &amp; Beverage Industry?<\/b><\/p>\n<p><span style=\"font-weight: 400;\">GLP-1 weight loss medications present a dynamic challenge and opportunity for the Food &amp; Beverage industry. Companies that can adapt to changing consumer preferences, innovate new product lines, and effectively market their offerings stand to benefit. Whether those who are reliant on traditional, high-calorie products will face bottom line impacts remains to be seen.<\/span><\/p>\n<h2><b>\u00a0<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">To find out more about what other topics are driving mainstream media coverage and social media conversations about the world\u2019s leading Food &amp; Beverage brands and their CEOs, download our report: <\/span><a href=\"https:\/\/onclusive.com\/en-gb\/resources\/whitepaper\/ceo-index-food-and-beverages\/\"><b>Food &amp; Beverage CEOs &amp; Their Brands in the Media.\u00a0<\/b><\/a><\/p>\n \n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\t\t\n\t\t\t<div class=\"post_content--wrapper\">\n\t\t\t\t<div class=\"post_content--pullout_copy  \">\n\t\t\t\t\t<div class=\"post_content--pullout_copy-inner-wrapper\">\n\n\n\t\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"post_content-copy-wrapper\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<blockquote class=\"pullout_copy\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t  \t\t<p><span style=\"color: #ffffff;\">Learn more about our media monitoring tools and how they can provide critical insights for your strategies. <a style=\"color: #ffffff;\" href=\"https:\/\/onclusive.com\/en-gb\/talk-to-us\/\">Contact us for a demo.<\/a><\/span><\/p>\n \n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/blockquote>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\t\t\n<\/section> \n\n\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":33,"featured_media":49402,"comment_status":"closed","ping_status":"open","sticky":false,"template":"blog-post-new-template.php","format":"standard","meta":{"_acf_changed":false,"content-type":"","inline_featured_image":false,"footnotes":""},"audience":[379,380],"topic":[1336,1426],"region":[],"class_list":["post-49352","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","audience-government-public-sector-3","audience-pr-agencies-2","topic-competitive-intelligence-en-gb","topic-media-monitoring-en-gb"],"acf":[],"_links":{"self":[{"href":"https:\/\/onclusive.com\/en-gb\/wp-json\/wp\/v2\/posts\/49352","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/onclusive.com\/en-gb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/onclusive.com\/en-gb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/onclusive.com\/en-gb\/wp-json\/wp\/v2\/users\/33"}],"replies":[{"embeddable":true,"href":"https:\/\/onclusive.com\/en-gb\/wp-json\/wp\/v2\/comments?post=49352"}],"version-history":[{"count":0,"href":"https:\/\/onclusive.com\/en-gb\/wp-json\/wp\/v2\/posts\/49352\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/onclusive.com\/en-gb\/wp-json\/wp\/v2\/media\/49402"}],"wp:attachment":[{"href":"https:\/\/onclusive.com\/en-gb\/wp-json\/wp\/v2\/media?parent=49352"}],"wp:term":[{"taxonomy":"audience","embeddable":true,"href":"https:\/\/onclusive.com\/en-gb\/wp-json\/wp\/v2\/audience?post=49352"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/onclusive.com\/en-gb\/wp-json\/wp\/v2\/topic?post=49352"},{"taxonomy":"region","embeddable":true,"href":"https:\/\/onclusive.com\/en-gb\/wp-json\/wp\/v2\/region?post=49352"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}